MANE.US Veradermics, Incorporated

Healthcare Biotechnology USA Stocks
129.66 USD
Close of Nov 15, 2026
32.00 156.63
Market cap
USD 5.47B
P/E
-
P/B
6.87x
ROE
-12.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MANE.US undervalued?

Graham number

The Graham number of Veradermics, Incorporated cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Veradermics, Incorporated fundamental analysis

No fundamental analysis for Veradermics, Incorporated yet.

Veradermics, Incorporated stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Veradermics, Incorporated

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunother…

Full company profile